FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077027462> ?p ?o ?g. }

• W2077027462 endingPage "49" @default.
• W2077027462 startingPage "44" @default.
• W2077027462 abstract "Current guidelines for antidepressant use recommend 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. This study evaluates the efficacy and safety of continuation escitalopram treatment.Outpatients diagnosed with DSM-IV major depressive disorder (male or female, aged 18 to 81 years) who had completed 8 weeks of randomized double-blind treatment with escitalopram, citalopram, or placebo entered an 8-week flexible-dose, open-label phase in which all patients received escitalopram (10-20 mg/day). This study was initiated November 3, 1999, and completed April 5, 2001. Patients who met responder criteria (score of < or = 12 on the Montgomery-Asberg Depression Rating Scale [MADRS]) were randomly assigned in a 2:1 ratio to escitalopram (at the dose each patient was receiving at the end of the open-label phase) or placebo for 36 weeks of double-blind treatment. The primary efficacy variable was time to depression relapse (defined as MADRS score > or = 22 or discontinuation due to an insufficient therapeutic response) from the start of the double-blind treatment phase.A total of 502 patients received open-label escitalopram treatment and had at least 1 MADRS assessment. A total of 274 evaluable subjects entered the double-blind treatment phase; 93 received placebo and 181 received escitalopram. Time to depression relapse was significantly longer (p =.013) and the cumulative rate of relapse was significantly lower in patients who received escitalopram (26% escitalopram vs. 40% placebo; hazard ratio = 0.56; p =.01). Escitalopram-treated subjects had significantly lower depression ratings than those of placebo-treated patients. Escitalopram continuation treatment was safe and well tolerated. Discontinuation rates due to adverse events were 7% for the placebo group and 4% for the escitalopram-treated group.Continuation treatment with escitalopram is effective in preventing relapse into an episode of major depressive disorder." @default.
• W2077027462 created "2016-06-24" @default.
• W2077027462 creator A5010706583 @default.
• W2077027462 creator A5027777637 @default.
• W2077027462 creator A5058590839 @default.
• W2077027462 date "2004-01-15" @default.
• W2077027462 modified "2023-09-28" @default.
• W2077027462 title "Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes" @default.
• W2077027462 cites W119739424 @default.
• W2077027462 cites W1583327662 @default.
• W2077027462 cites W1759860330 @default.
• W2077027462 cites W189854980 @default.
• W2077027462 cites W1982377331 @default.
• W2077027462 cites W2039577238 @default.
• W2077027462 cites W2044359142 @default.
• W2077027462 cites W2049248052 @default.
• W2077027462 cites W2058750823 @default.
• W2077027462 cites W2072698152 @default.
• W2077027462 cites W2099564543 @default.
• W2077027462 cites W2114613490 @default.
• W2077027462 cites W2131823335 @default.
• W2077027462 cites W2133308299 @default.
• W2077027462 cites W2145806711 @default.
• W2077027462 cites W2151185329 @default.
• W2077027462 cites W2151845762 @default.
• W2077027462 cites W2158910272 @default.
• W2077027462 cites W2415689313 @default.
• W2077027462 cites W3022677499 @default.
• W2077027462 cites W3090293687 @default.
• W2077027462 cites W428598680 @default.
• W2077027462 cites W598623070 @default.
• W2077027462 cites W3148767351 @default.
• W2077027462 doi "https://doi.org/10.4088/jcp.v65n0107" @default.
• W2077027462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14744167" @default.
• W2077027462 hasPublicationYear "2004" @default.
• W2077027462 type Work @default.
• W2077027462 sameAs 2077027462 @default.
• W2077027462 citedByCount "113" @default.
• W2077027462 countsByYear W20770274622012 @default.
• W2077027462 countsByYear W20770274622013 @default.
• W2077027462 countsByYear W20770274622014 @default.
• W2077027462 countsByYear W20770274622015 @default.
• W2077027462 countsByYear W20770274622016 @default.
• W2077027462 countsByYear W20770274622017 @default.
• W2077027462 countsByYear W20770274622019 @default.
• W2077027462 countsByYear W20770274622020 @default.
• W2077027462 countsByYear W20770274622021 @default.
• W2077027462 countsByYear W20770274622022 @default.
• W2077027462 countsByYear W20770274622023 @default.
• W2077027462 crossrefType "journal-article" @default.
• W2077027462 hasAuthorship W2077027462A5010706583 @default.
• W2077027462 hasAuthorship W2077027462A5027777637 @default.
• W2077027462 hasAuthorship W2077027462A5058590839 @default.
• W2077027462 hasConcept C118552586 @default.
• W2077027462 hasConcept C126322002 @default.
• W2077027462 hasConcept C139719470 @default.
• W2077027462 hasConcept C142724271 @default.
• W2077027462 hasConcept C15744967 @default.
• W2077027462 hasConcept C162324750 @default.
• W2077027462 hasConcept C168563851 @default.
• W2077027462 hasConcept C169900460 @default.
• W2077027462 hasConcept C197934379 @default.
• W2077027462 hasConcept C204787440 @default.
• W2077027462 hasConcept C27081682 @default.
• W2077027462 hasConcept C2776867660 @default.
• W2077027462 hasConcept C2777490545 @default.
• W2077027462 hasConcept C2778375690 @default.
• W2077027462 hasConcept C2778715236 @default.
• W2077027462 hasConcept C2779177272 @default.
• W2077027462 hasConcept C2779583969 @default.
• W2077027462 hasConcept C2780051608 @default.
• W2077027462 hasConcept C558461103 @default.
• W2077027462 hasConcept C71924100 @default.
• W2077027462 hasConceptScore W2077027462C118552586 @default.
• W2077027462 hasConceptScore W2077027462C126322002 @default.
• W2077027462 hasConceptScore W2077027462C139719470 @default.
• W2077027462 hasConceptScore W2077027462C142724271 @default.
• W2077027462 hasConceptScore W2077027462C15744967 @default.
• W2077027462 hasConceptScore W2077027462C162324750 @default.
• W2077027462 hasConceptScore W2077027462C168563851 @default.
• W2077027462 hasConceptScore W2077027462C169900460 @default.
• W2077027462 hasConceptScore W2077027462C197934379 @default.
• W2077027462 hasConceptScore W2077027462C204787440 @default.
• W2077027462 hasConceptScore W2077027462C27081682 @default.
• W2077027462 hasConceptScore W2077027462C2776867660 @default.
• W2077027462 hasConceptScore W2077027462C2777490545 @default.
• W2077027462 hasConceptScore W2077027462C2778375690 @default.
• W2077027462 hasConceptScore W2077027462C2778715236 @default.
• W2077027462 hasConceptScore W2077027462C2779177272 @default.
• W2077027462 hasConceptScore W2077027462C2779583969 @default.
• W2077027462 hasConceptScore W2077027462C2780051608 @default.
• W2077027462 hasConceptScore W2077027462C558461103 @default.
• W2077027462 hasConceptScore W2077027462C71924100 @default.
• W2077027462 hasIssue "1" @default.
• W2077027462 hasLocation W20770274621 @default.
• W2077027462 hasLocation W20770274622 @default.
• W2077027462 hasOpenAccess W2077027462 @default.
• W2077027462 hasPrimaryLocation W20770274621 @default.

• next